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Lost in Translation
David H. Wasserman, Julio E. Ayala, and Owen P. McGuinness
T
here are few methodologies that have done more
to advance our understanding of insulin action in
humans and animals than the hyperinsulinemic-
euglycemic clamp (henceforth referred to as the
insulin clamp or clamp). The clamp was ﬁrst developed for
use in humans by DeFronzo, Tobin, and Andres at Johns
Hopkins in 1979 (1). This technique was transferred to the
rat in 1983 (2,3) and the mouse in the early 1990s (4,5). The
insulin clamp is often combined with isotopic methods so
that the investigator cannot only determine a total whole-
body insulin action but also how speciﬁc tissues and
metabolic pathways are affected. The adaptation of the
insulin clamp for use in the mouse has been critical to the
characterization of the still growing number of mouse
models with modiﬁcations to the genes involved in the
regulation of glucose and energy homeostasis. Despite the
importance of this tool, a signiﬁcant deﬁciency has
evolved in the process of translating the clamp from
humans to mice. The ﬁrst articles reporting insulin clamps
in the mouse conscientiously presented methods and
results (4,5). However, since these ﬁrst studies in the
mouse, the care and conventions of the human clamp
literature that immediately followed its development have
largely been traded for no, minimal, or inaccurate descrip-
tion of methods and inadequate presentation of results.
The reader is provided with too little information to
independently interpret the results of an article. Instead,
the reader is solely dependent on the conclusion to which
he or she is directed by the authors. The perception that
standards in the human and rat literature have lowered in
recent years was brought to our attention during the
preparation of this article. Here, we focus on the mouse
literature. Of course, sound reporting of clamp methods
and results applies to all species. The purpose of this
article is to see how the careful presentations of the initial
human insulin clamp studies might be better translated to
the mouse insulin clamp literature. We will outline the
problem and cite speciﬁc examples where failure to
present clamps in a complete and accurate manner has
had a negative impact. We will convey our view as to what
investigators using the insulin clamp should include in
published reports and what reviewers should require of
them so that the reader can independently interpret the
experiment.
Vagaries. The insulin clamp is challenging and subject to
variations that are speciﬁc to the laboratory in which they
are conducted. Despite these challenges and nuances, the
clamp has been the object of very little scrutiny when
applied to the mouse. Ayala et al. (6) ﬁrst reported this
deﬁcit in 2006. Our sense is that some improvements have
occurred with regards to the description of insulin clamps
since this ﬁrst statement of the problem. Nevertheless,
many problems remain. Let us provide some examples. In
2004 and 2005, nearly half (44%) of studies in mice failed to
report a sampling site (6). In the 2 years following the
publication of Ayala et al. (6), this number has dropped to
30%. Although this is an improvement, failure to indicate
a sampling site in nearly one-third of published studies
remains a deﬁciency in the ﬁeld. One area where little has
changed in the mouse clamp literature is the reporting of
insulin doses and insulin levels. Prior to 2006, 48% of
studies in mice mention a priming dose of insulin but fail
to indicate the actual dose. For reasons described in detail
later, this is not a trivial point. Furthermore, in almost all
of these studies, absolute insulin levels (fasting and
clamp) were not reported. It is impossible for a reader to
know that hyperinsulinemia has been achieved and insulin
levels are comparable between groups if insulin levels are
not reported. Since 2006, the percentage of published reports
that fail to indicate the priming dose of insulin and insulin
levels was still 40%. Finally, to date 90% of reports where
insulin clamps were performed in mice do not show a time
course of glucose levels and glucose infusion rates. Without
this information, one cannot know whether a steady-state
clamp has been achieved. Nearly all clamp experiments in
humans present these three parameters: sampling site, insu-
lin dosing/levels, or time course of glucose and glucose
infusion. It is therefore unclear to us why standards for the
mouse clamp literature should be any different.
The previous paragraph describes some fundamental
omissions in the mouse clamp literature. Without the
presentation of fundamental clamp components such as
time course of glucose and glucose infusion it is impossi-
ble to know whether a clamp has been performed. This is
not to say that from time to time certain vital information
may be inadvertently left on the cutting room ﬂoor. A
minimalist approach to the description of procedure and
presentation of results is almost convention. A curious
tangential observation is that whereas insulin clamps in
the mouse are often poorly described or not described at
all, glucose tolerance tests and insulin tolerance tests are
described reasonably well. Methodology is usually ade-
quately presented, and time courses are shown. The
results from well-conducted glucose tolerance tests and
insulin tolerance tests are more interpretable than an
insulin clamp that does not report clamp insulin concen-
trations. In the same vein, there are articles that provide
little to no information on the clamp but will describe a
routine published buffer system or assay with great detail.
The question thus remains, why has the insulin clamp been
lost in translation to the mouse?
An example illustrating the vagaries that are pervasive
in the mouse clamp literature is evident in the ambiguous
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common method during a clamp for obtaining blood from
a mouse is to bleed it by slicing the tip of the tail off and
compressing the tail so that blood drips from it (6). Some
choose to restrain the mouse during this procedure. The
advantage of this procedure is that it does not require the
technically difﬁcult implantation of an arterial sampling
catheter, which is another common method for obtaining
blood samples (6,7). The drawback is that blood does not
always ﬂow freely from the cut tail necessitating constant
squeezing of the tail, especially when larger samples are
needed for hormone and isotopic tracer analysis.
Except for Ayala et al. (6), no published report has
indicated levels of stress hormones when using cut-tail
sampling during insulin clamps in mice. Indeed, several
otherwise nonideal approaches that have been taken
might minimize the perception of stress in a study. These
include 1) glycogen depletion via overnight fasting that
limits stress-induced hyperglycemia, 2) beginning clamps
with a pharmacological bolus of insulin that lower stress-
induced hyperglycemia, and 3) presentation of average,
rather than time course, glucose levels that dampen the
appearance of glucose variability induced by stress. An-
other commonly used approach is to state that a “tail-
restraint” method was used to conduct experiments with
“minimal stress” (8). Minimal stress is not deﬁned, and
there is no indication that this was evaluated with a
scientiﬁc method. Furthermore, the description of the
sampling method in this way is deceptive because it does
not indicate that 1) the tip of the tail has been cut off and
2) the entire mouse, and not just the tail, is restrained.
Furthermore, it does not describe the means by which the
tail is compressed to obtain blood from the wound. This is
signiﬁcant because this means of handling the tail is the
primary source of stress that occurs due to this sampling
method (6). More recently, a statement to the effect that
blood was obtained from tail vessels (9) has also been
used as a concise way of indicating that the tip of the tail
was cut, the mouse was restrained, and blood was dripped
from the wound. The shortcoming with all of these com-
mon approaches to describing the insulin clamp is that
while they reduce the perception of stress by the person
reading the manuscript they have no bearing on whether
the mice are stressed. The approach of cutting the tail to
obtain blood has been used in our laboratory (10) and is of
value for mice that do not handle the carotid catheteriza-
tion surgery well (e.g., ob/ob mice). In addition, the cut-tail
approach is a valuable tool because the surgical skills
required for carotid catheterization are quite specialized.
Useful information can certainly be and has been obtained
from the approach of obtaining blood from the cut tail.
However, it is important to be transparent about the
sampling technique used in an experiment because the
results may differ due to stress or other factors.
The use of a carotid artery catheter for sampling is not
without problems (i.e., difﬁcult surgery, longer postopera-
tive period, and possibility of stroke). Different sampling
methods have advantages and disadvantages. The impor-
tant distinction is that investigators who use a carotid
artery catheter in experiments are clear in the reporting,
whereas many investigators who use the tail are not.
Regardless, the need for accurate reporting is not trivial
because differences in stress induced by sampling method
may exist (6) and also the composition of the sample is
different because the blood dripped from the tail is arterial
and venous (plus a small amount of lymph).
One factor that has allowed for the vagaries of the
mouse clamp to evolve is the illusion that a seminal
reference exists that contains all the missing information.
In a few cases, appropriate clamp method references do
exist (6,7,11,12). Often the reader will be sent on a trail of
unrelated citations. Methods reporting of an insulin clamp
should at the very least include 1) surgical procedures if
applicable, 2) infusion and sampling ports, 3) insulin
delivery protocol, 4) isotope delivery protocol if applica-
ble, 5) fast duration, 6) restraint or anesthesia if applica-
ble, and 7) sample frequency for clamp feedback
measurements of blood glucose.
Reductionism. There are some very difﬁcult issues asso-
ciated with performing clamps on the conscious mouse.
One such limitation pertains to the relatively small volume
of blood in the mouse (2 ml). Clearly, one has to scale
down assay volumes and be judicious in sampling. Circu-
lating glucose must be measured at frequent intervals
throughout the clamp. However, measurements of clamp
insulin and isotope concentrations usually must be limited
to the interval just prior to the end of the clamp when
insulin action is in a steady state. Similarly, sampling for
the measurement of stress hormones usually must be
limited to the end of the clamp. Erythrocyte replacement
can sustain hematocrit and allow for more blood sampling.
The small blood volume of the mouse does not allow for
the same scope of blood sampling that can be undertaken
in the human and large animal models. Sampling volume
can be increased by infusing blood from an appropriately
matched donor mouse. This, however, adds some com-
plexity to the experiment and requires an increase in the
mouse colony size. Clearly, the limitation in blood volume
is all the more reason to present the data that are obtained
during a clamp.
Blood or plasma glucose concentrations are measured
throughout an insulin clamp. The measurement of circu-
lating glucose online is the feedback from which the
glucose infusion rate used to maintain euglycemia is
based. A study is not a clamp without the regular measure-
ment of glucose and the iterative adjustment of glucose
infusion. Even though these data must exist if a clamp was
truly performed, they are rarely presented. These are vital
data because they demonstrate the quality of the clamp,
whether steady states in blood glucose and insulin action
were obtained, and the kinetics of insulin action (i.e., the
rapidity of onset). These data are not at all trivial, espe-
cially when one considers that the rate of glucose ﬂux is
approximately seven times higher in mice than humans.
This means that for a given mismatch in glucose infusion
rate to glucose requirement, a greater deviation in circu-
lating glucose will occur in mice than humans. As noted
above, almost every insulin clamp study conducted in
humans shows time courses for blood glucose and glucose
infusion rate. Despite the added vulnerability of mice to
deviations in blood glucose, very few insulin clamp studies
conducted in mice show a time course of glucose and
glucose infusion rates. Instead, the convention in the
mouse clamp literature is to present average values for
these parameters. Thus, the content of a clamp that
generally lasts about2hi sreduced to a single point. One
is left to speculate in many cases what that single point
represents. The consequence of this reductionism is that it is
impossible for any reader to interpret whether a clamp was
truly achieved.
Results from an insulin clamp are meaningless if the
absolute fasting and clamp insulin levels are not reported.
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hyperinsulinemia had been achieved? Differences in insu-
lin concentrations can occur between genotypes, in re-
sponse to dietary manipulations, or due to drug
treatments, even when the insulin infusion rate is identical
(13–15). Given the importance of this parameter, it is
perplexing that many investigators performing clamps
on mice do not report insulin concentrations. Instead,
the convention has been to state that insulin infusions
were done to “achieve physiological hyperinsulinemia.”
Actual empirically determined insulin measurements
are not, however, reported. The use of speculated plasma
insulin concentrations is problematic on many fronts. As
mentioned, experimental manipulations can affect insulin
levels among groups receiving equal insulin infusions.
Furthermore, this practice renders the deﬁnition of “phys-
iological hyperinsulinemia” as arbitrary. Illustrating this,
speculated insulin concentrations obtained with an insulin
infusion rate of 15 pmol  kg
1  min
1 from one laboratory
fell from 850 (16) to 780 (17) to 650 (18) to 600 (19) to
400–500 (20) to 350 (21) to 300 (11) to 200 (22) pmol/l over
a period ranging from 2000–2005. These declining esti-
mates were made independent of genotype or treatment
and apparently independent of actual chemical analysis.
Results reporting an insulin clamp should at the very
least include 1) the time course for circulating glucose and
the glucose infusion rate, 2) an index that shows whether
or not glucose-speciﬁc activity is constant during the
steady-state sampling period if applicable, 3) plasma insu-
lin concentration before and during the clamp, and 4)
hematocrit. If possible, an end-study stress hormone level
or some other stress marker would provide a useful
validation test of the clamp procedure.
Perpetuity. Up to this point we have outlined deﬁcits in
the presentation of the methods and data. Here, we show
why this is a very real problem. Like any other experiment,
the study design determines the outcome of an insulin
clamp in mice (6). Although certain modiﬁcations have
improved the methodology, other variations have arisen in
insulin clamp protocols that appear to be based on con-
ceptual ﬂaws. Two such modiﬁcations, as discussed be-
low, have been incorporated into a signiﬁcant component
of the literature and are still being used by some labora-
tories. These conceptual errors have persisted in the
literature because the descriptions of the pertinent proto-
cols are generally inadequate to identify the ﬂawed proce-
dure. Thus, the failure to provide methods in articles has
had repercussions. The absence of peer review of these
ﬂawed techniques has allowed them to infect the literature
in perpetuity. These major ﬂaws were eventually uncov-
ered when the methodology was ﬁnally described in a
careful and accurate manner (23). The unfortunate reality
that became clear is that approximately half the literature
up to that point appears to carry these signiﬁcant concep-
tual errors. These errors are described below.
One mistake is that the insulin priming dose used in
many studies is 50% of the total insulin administered and
20 times the amount needed to expedite steady-state
insulin concentrations. The origin of this mistake can be
traced from information in the study of Haluzik, Gavrilova,
and LeRoith (23), and it is likely contained but not
described in more than 50 published reports. A study of
the impact of the large insulin bolus has been performed in
wild-type mice (6). Complicating the impact of the insulin
megabolus is the probability that the resulting supraphar-
macological insulin concentration will be dependent on
the model being studied (i.e., genotype or pharmacological
treatment). First-phase insulin secretion has persistent
effects that last well after its cessation (24,25). One can
equate the large insulin bolus to a hyperexaggerated
ﬁrst-phase insulin secretory response. The use of an
excessively large insulin bolus is still common, although in
some laboratories it has been scaled down to 10 times
the amount calculated to expedite steady-state insulin
concentrations (15,26,27).
The second modiﬁcation to the standard insulin clamp
that crept into protocols used in some laboratories is that
a bolus of [3-
3H]glucose (10 Ci) is given in the middle of
the study. This priming dose is administered after a
[3-
3H]glucose steady state has already been obtained! This
is in addition to or in place of the correct [3-
3H]glucose
priming dose that is administered at the start of the tracer
infusion. The incorrect tracer prime is administered so
that it coincides with the onset of the primed insulin
infusion. This makes sense qualitatively if one assumes
that the insulin dose increases the glucose volume of
distribution (i.e., accumulation of intracellular glucose).
The problem is with the magnitude of the tracer bolus. A
tracer primer is calculated as the product of the tracee
(glucose) pool size and the target glucose–speciﬁc activity.
Under commonly used insulin clamp conditions, it could
be projected that a bolus of 10 Ci is large enough to label
the glucose pool if it ﬁlled the entire body-water space at
concentrations comparable with blood glucose (assuming
a [3-
3H]glucose infusion rate of 0.1 Ci/min). The large
tracer bolus disrupts blood [3-
3H]glucose steady state and
ﬂoods the system with radioactive glucose. The excess
[3-
3H]glucose should be quickly cleared from the blood.
The problem is that glycogen and H2O pools become
labeled with
3H. If one begins with information provided
by Haluzik, Gavrilova, and LeRoith (23), it is possible to
roughly estimate the number of articles that are affected.
Like the insulin megabolus, the excessive ill-timed tracer
bolus is probably also contained but not described in more
than 50 articles.
For the same reason these problems arose (poor report-
ing of methods and results), it is impossible to know all the
articles that are marred by the technical and conceptual
mistakes outlined above, short of investigators submitting
corrigenda. It is also difﬁcult to know whether other
conceptual problems have infected the literature. Looking
forward, the solution to this problem is for reviewers and
editors to require transparency in the description of meth-
odology and presentation of results.
SUMMARY
Performing an insulin clamp is not akin to performing an
established chemical assay, in which all the reagents are
well established. Yet based on the lack of technical
descriptions and reductionism of results, one might as-
sume that an insulin clamp can be done with a few good
reagents and a kit. It should be clear that there are many
acceptable ways to perform a clamp. The speciﬁc insulin
clamp technique should accommodate the speciﬁc ques-
tion being addressed as well as the technical strengths of
the laboratory. Because there is more than one way to
perform a clamp on a mouse, the particular clamp proto-
col that is used should be described accurately. As exem-
pliﬁed by the circumstances described above, it is in the
best interests of the scientiﬁc community to provide an
accurate description of the clamp method so that critical
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above. To some extent, these methods were corrected
once they were ﬁnally identiﬁed (23). With regard to
presentation of results, there is no evidence that a clamp
was performed without presenting the time courses for
circulating glucose and glucose infusion rates. Likewise,
although it may seem obvious to measure insulin during an
insulin clamp, numerous articles fail to do so, rendering
such studies not interpretable.
One common refrain is that journals do not permit the
space for description of methods and presentation of
clamp results. There are other more reasonable ways to
save space. Certainly, the uninformative presentation of
blood glucose and glucose infusion rates as a histogram is
wasted space that would better serve the reader if it
were used to show a time course graph. Furthermore,
the growing popularity of supplemental sections negates
the argument that space is a limiting issue. Because the
mouse is so difﬁcult to study, it is logical and necessary to
present the few indexes that are available.
Once presentation of methodology and results becomes
routine, a serious and broader discussion of optimal clamp
techniques can begin. The insulin clamp procedure used at
the Vanderbilt Mouse Metabolic Phenotyping Center is
posted in great detail at the center Web site (www.mc.
vanderbilt.edu/mmpc). We realize that translation of the
clamp method from humans to mice is still an evolving
process. We have beneﬁted in the past from comments and
suggestions from participants in a course we offer each
year on glucose clamping as well as from other investiga-
tors interested in clamp technology. We hope for a contin-
ued exchange of information and for experimental
transparency that will improve the ability to glucose clamp
the conscious mouse.
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